GI Clinical Advisory Board

Evan S. Dellon is a Professor of Medicine and Adjunct Professor of Epidemiology at the University of North Carolina School of Medicine in Chapel Hill. Dr. Dellon received his undergraduate degree from Brown University and his medical degree from Johns Hopkins School of Medicine. He completed internship and residency in Internal Medicine at Massachusetts General Hospital. He performed a clinical and a research fellowship in Adult Gastroenterology at UNC, during which he also received a Masters of Public Health degree in Epidemiology from the UNC School of Public Health. Dr. Dellon is currently the Director of the UNC Center for Esophageal Diseases and Swallowing (CEDAS) and has served as an Associate Editor for Clinical Gastroenterology and Hepatology. Dr. Dellon’s main research interest is in the epidemiology, pathogenesis, diagnosis, treatment, and outcomes of eosinophilic esophagitis (EoE) and the eosinophilic GI diseases (EGIDs). The goal of his research is to improve the lives of patients with EoE and EGIDs by learning how to better diagnose, treat, and monitor these conditions.

Stephen E. Attwood is honorary professor in health services research at Durham University, UK, and an independent consulting advisor on research and clinical practice for oesophageal diseases. He qualified from Trinity College Dublin and took his Surgical Fellowship at the Royal College of Surgeons in Ireland. Most recently, he was a consultant surgeon at Northumbria Healthcare UK. Since identifying Eosinophilic Oesophagitis (EoE) in 1989 and publishing the first description of the disease in 1992, Professor Attwood has spent his career caring for patients with EoE. He has been actively engaged in clinical trials of upper gastrointestinal diseases, including budesonide formulations for EoE; the ASPECT trial of cancer prevention in Barrett’s esophagus; BEST3, a study of Cytosponge screening for Barrett’s esophagus in general practices; the LOTUS trial (surgery vs proton pump inhibitor for Gastroesophageal Reflux Disease). He has authored more than 200 publications, including the recent British Society of Gastroenterology Guidelines on EoE.

Albert J. (Arjan) Bredenoord is consultant gastroenterologist at the Amsterdam University Medical Center and professor of Neurogastroenterology & Motility at the University of Amsterdam. After his medicine studies in Antwerp, Belgium he worked on several clinical research projects on GI motility at the University of Utrecht, the Netherlands resulting in a PhD thesis on gastroesophageal reflux disease in 2006. His clinical training was performed in Nieuwegein, the Netherlands, and at the Royal London Hospital in London, UK. He currently works as a consultant gastroenterologist at the Amsterdam UMC where he is dedicated to patient care, scientific research and education in the field of benign esophageal diseases. Dr. Bredenoord’s main focus is on achalasia, reflux disease and EoE. He is one of the pioneers of high-resolution manometry and impedance monitoring of the esophagus. The esophageal clinic in the Amsterdam UMC hosts the largest population of benign esophageal diseases in the Netherlands. Dr. Bredenoord is an author of over 350 papers, books and book chapters and organizes regular courses in Europe, North America and Asia. Dr. Bredenoord was President of the European Society of Eosinophilic Esophagitis (EUREOS) between 2017 and 2021 and president of the Dutch GI Motility society between 2014-2019, he is a member of the Amsterdam UMC Institutional Review Board, UEG Scientific Committee, Dutch GI education committee and co-founder of the International HRM working group.

Donna Griebel is a regulatory consultant with Griebel and Rosebraugh Consulting, LLC. She retired from Food and Drug Administration (FDA) in 2018 after having served as Division Director of the Division of Gastroenterology and Inborn Errors Products (with the Office of New Drugs in the Center for Drug Evaluation and Research) for approximately a decade. Her prior CDER/FDA leadership roles included Deputy Director of Division of Reproductive and Urologic Drug Products and Clinical Team Leader in Division of Oncology Drug Products.

Roos Pouw obtained her degree in Medicine at the University of Utrecht and a research fellowship at Harvard Medical School in Boston before starting her career in gastroenterology with a PhD fellowship at the Academic Medical Centers, Amsterdam, the Netherlands. In 2011 she obtained her PhD-degree Cum Laude with her thesis titled "Endoscopic eradication of Barrett's esophagus with early neoplasia". During her training as a gastroenterologist in Amsterdam at the former Academic Medical Center (AMC), she focused on endoscopic detection and treatment of early upper gastrointestinal neoplasia. After finishing her training in 2017, Dr. Pouw was appointed staff member at the Dept. of Gastroenterology and Hepatology at AMC, currently known as the Amsterdam University Medical Centers. Dr. Pouw’s clinical work focuses on offering a wide range of endoscopic treatments to patients with upper gastrointestinal neoplasia. In addition to her clinical work, Dr. Pouw is principal investigator and supervises a number of research lines on endoscopic management of early Barrett's neoplasia, and for this work, she received the United European Gastroenterology (UEG) Rising Star award in 2020. She also supervises a research line on endoscopic vacuum therapy for treatment of defects in the upper gastrointestinal tract. Dr. Pouw is co-chair of the Young International Society for Diseases of the Esophagus (ISDE), secretary of the Dutch Upper Cancer Group, national representative for UEG, task force leader for a number of guideline initiatives and curricula on esophageal neoplasia for the European Society of Gastrointestinal Endoscopy (ESGE) and ISDE, and editorial (advisory) board member for the UEG Journal and Best Practice & Research: Clinical Gastroenterology.